1. Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study. Issue 7 (July 2022) Authors: Wechsler, Michael E; Menzies-Gow, Andrew; Brightling, Christopher E; Kuna, Piotr; Korn, Stephanie; Welte, Tobias; Griffiths, Janet M; Sałapa, Kinga; Hellqvist, Åsa; Almqvist, Gun; Lal, Harbans; Kaur, Primal; Skärby, Tor; Colice, Gene; Cambursano, Victor H; Fernandez, Marcelo J; Scherbovsky, Ferna... Journal: Lancet Issue: Volume 10:Issue 7(2022) Page Start: 650 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study. Issue 5 (May 2023) Authors: Menzies-Gow, Andrew; Wechsler, Michael E; Brightling, Christopher E; Korn, Stephanie; Corren, Jonathan; Israel, Elliot; Chupp, Geoffrey; Bednarczyk, Artur; Ponnarambil, Sandhia; Caveney, Scott; Almqvist, Gun; Gołąbek, Monika; Simonsson, Linda; Lawson, Kaitlyn; Bowen, Karin; Colice, Gene; Hetzel, ... Journal: Lancet Issue: Volume 11:Issue 5(2023) Page Start: 425 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗